Complete our comprehensive health questionnaire, receive expert prescriber review, and have your medication dispatched the same day for next day delivery
The relationship between these conditions is complex, with obesity being a significant risk factor for developing type 2 diabetes, whilst diabetes itself can make weight management more challenging
Knowing why weight loss sometimes stalls on GLP-1 therapy helps tirzepatide users troubleshoot similar issues when they arise
-Eligible beneficiaries must be: -Age 18 or older with a BMI of 35 or higher when treatment begins, or -Age 18 or older with a BMI of 27.5 or higher and at least one qualifying high-risk condition, including: -Prediabetes -Previous heart attack or stroke -Heart failure -Symptomatic peripheral artery disease -Chronic kidney disease Who is not eligible
Semaglutide causes a delay of gastric emptying and thereby has the potential to impact the absorption of concomitantly administered oral medications
It is an analog of angiotensin IV, an oligopeptide, and is orally active and crosses the blood-brain barrier